No description available.

Trata-se de um estudo caso-controle de câncer de reto como parte do \"Estudo Epidemiológico de Câncer de Esôfago e de Reto no Município de são Paulo\". O estudo compreendeu 92 casos de cancer de reto e 200 controles categorizados em 3 sub-conjuntos (amostra pareada, global e estratificada). Foram objeto de análise as variáveis: local de nascimento do indivíduo e de seus pais, zona de nascimento (rural/urbana) consumo de alimentos (carnes, ovos, verduras, temperos) características do hábito intestinal, tabagismo e consumo de bebidas (cerveja, vinho e pinga). As estimativas dos Riscos Relativos (RR) por ponto e respectivos testes de significância foram calculados para cada tipo de amostra. Utilizou-se análise multivariada, através do procedimento de máxima verossimilhança condicional para a amostra estratificada e os procedimentos clássicos para as amostras pareada e global. A análise estatística dos resultados evidenciou associação positiva apenas entre o consumo de queijo e câncer de reto (RR = 1,41 I--------I 4,30). Não está afastada a possibilidade de que a significância encontrada seja devido a um artefato estatístico, dada a multiplicidade de testes efetuados. A possível associação entre o consumo queijo e câncer de reto, portanto, deve ser interpretada com reserva. / This is a case-control study of rectal cancer and is part of \"The Epidemiological Study of Esophagus and Rectal Cancers in the City of são Paulo, Brazil\". The study included 92 cases of rectal cancer and 200 controls (classified in three types: matched, global and stratified samples). The analised variables were: state of birth classified in great regions of Brazil, place of birth (rural/urban) ,food consumption (meats, eggs, fruits, vegetables, cereals, beans, seasonings, dairy products) caracteristics of the bowel movements, smoking habits and alcohol consumption (beer, wine and hard liquor-\"pinga\"). The point estimates of the Relative Risks and their significance tests were calculated for each type of sample. Multivariate analysis was done, for the stratified sample the conditional maximum likelihood procedure was used and classical procedures (Me Nemar and Cross Ratio estimate) for the other samples. The statistical analysis indicated a positive/association only between cheese consumption and cancer of the rectum (RR = 1,41 I------I 4,30). There is the possibility that the observed statistical significance is a statistical artefact due to the multiplicity of tests that have been perfomed. Because of this, the possible association between cheese consumption and cancer of the rectum must be viewed with caution.

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第22325号 / 医博第4566号 / 新制||医||1041(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 妹尾 浩, 教授 萩原 正敏, 教授 小川 修 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

Management of very low rectal cancer is one of the most challenging issues faced by colorectal surgeons. For tumors in the mid and upper rectum, procedures can be done to resect the cancer while maintaining continence, a major determinant of post-operative quality of life. In the low rectum, however, to optimize oncologic outcomes, many surgeons feel compelled to pursue abdominoperineal (APR) over low anterior resection (LAR), a sphincter-preserving procedure. It was hypothesized that after robust adjustment, procedure choice will not be associated with a difference in disease-free survival in the resection of tumors in the low rectum. To analyze this, the US Rectal Cancer Collaborative Database, a comprehensive, multi-center dataset obtained from six institutions between 2010 and 2016, was queried. Patients undergoing TME resection for Stage I-III very low rectal cancers (involvement) were selected for this study. Patients were categorized by procedure- LAR vs APR. Primary outcome was five-year disease-free survival. Secondary outcomes included overall survival, recurrence, length of stay, and complications. An adjusted analysis was performed to account for all known potential confounders. 431 patients with very low rectal cancer treated by either APR or LAR were identified. 154 (35.7%) underwent APR. The overall recurrence rate was 19.6%. Median follow-up time was 42.5 months. An analysis adjusted for age, gender, BMI, ASA class, and pathologic stage observed no difference in disease free survival between operative types (HR=0.90, 95% CI [0.53-1.52], p=0.70). Similarly, secondary outcomes demonstrated no significant difference between operation types, including length of stay (Beta: 0.04, Std. error = 0.25, p = 0.54), overall survival (HR=1.29, 95% CI [0.71-2.32], p=0.39), or complications (OR = 1.53, 95% CI [0.94 - 2.50], p=0.09). In this analysis, no significant difference in disease-free survival or overall survival was observed between patients undergoing APR or LAR for very low rectal cancer. This comprehensive study supports the treatment of very low rectal cancer, less than 5cm from the anorectal ring with no sphincter involvement, by either abdominal perineal or low anterior resection. Further studies may focus on patient-reported and quality of life outcomes which may influence decision-making.

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第20800号 / 医博第4300号 / 新制||医||1025(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 武藤 学, 教授 福原 俊一, 教授 福田 和彦 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

Diss. (sammanfattning) Stockholm : Karol. inst., 2005. / Härtill 5 uppsatser.

No description available.

El texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado. / OBJECTIVE: Determine the impact of HIV-1 seroconversion on inflammatory cytokines in the rectal mucosa. SETTING: Secondary analysis of data from men who have sex with men and transgender women who participated in a HIV prevention trial Lima, Peru. METHODS: From July to December 2017, 605 men who have sex with men and transgender women were screened for rectal gonorrhea/chlamydia (GC/CT). Fifty GC/CT-positive cases were randomly selected and matched with 52 GC/CT-negative controls by age and number of receptive anal intercourse partners in the last month. All participants were HIV-negative at baseline and those with GC/CT at baseline and/or follow-up received appropriate antibiotic therapy. Participants underwent sponge collection of rectal secretions for the measurement of inflammatory cytokines (IL-1β, IL-6, IL-8, and TNF-α) and were screened for rectal GC/CT and HIV at baseline, 3 months, and 6 months. Wilcoxon rank-sum tests compared inflammatory cytokine levels between participants diagnosed with HIV during follow-up and persons who remained HIV-negative. RESULTS: Eight participants were diagnosed with HIV at the 3-month (n = 6) or 6-month (n = 2) visit. The median number of receptive anal intercourse partners in the month before HIV diagnosis was the same for those who acquired HIV and those who did not. There were no significant differences in inflammatory cytokine levels in rectal mucosa between participants who did and did not experience HIV seroconversion at any time point. CONCLUSIONS: Despite a surge in viral replication during acute infection, findings from this study suggest that there is no prolonged effect of HIV-1 seroconversion on inflammatory cytokine levels in the rectal mucosa. Copyright / National Institute of Allergy and Infectious Diseases / Revisión por pares

A cirurgia ainda é o principal método de tratamento do câncer do reto. Recentemente a quimio e radioterapia neo-adjuvantes têm sido preconizadas, com freqüência cada vez maior, com o intuito de reduzir os índices de recidiva e mortalidade. O objetivo desse estudo foi avaliar, retrospectivamente a sobrevida e a recidiva tumoral de pacientes submetidos a quimioterapia adjuvante, com e sem quimio e radioterapia neoadjuvantes. Foram avaliados retrospectivamente 36 pacientes submetidos a ressecção anterior baixa por adenocarcinoma do reto. Subdivididos em três grupos: grupo I (N=11), submetidos exclusivamente a tratamento cirúrgico; grupo II (N=8), submetidos a tratamento cirúrgico, seguido de quimioterapia adjuvante; grupo III (N=17), submetidos a tratamento cirúrgico com quimio e radioterapia neo-adjuvantes. O período de seguimento foi de 36 meses. Seis pacientes (16,6%) apresentaram recidiva, sendo 1 paciente do grupo I, 3 pacientes do grupo II e 2 pacientes do grupo III. A sobrevida global foi de 88,9%, assim distribuída: grupo I, 80,0%; grupo II, 100,0% e grupo III, 87,5%. Não houve diferença significante nos índices de recidiva nem na sobrevida entre os grupos. Concluiu-se que na amostra estudada os métodos terapêuticos tiveram resposta equivalente, não tendo sido possível demonstrar a interferência da quimio e ou radioterapia nos índices de sobrevida ou recidiva / Surgery continues to be the principal method for treating cancer of the rectum. Recently, chemo and neo-adjuvant radiotherapy have been considered, with increasing frequency, with the intention of reducing the rates of recurrence and mortality. The objective of this study was to evaluate, retrospectively, survival and tumor recurrence in patients submitted to adjuvant chemotherapy, with and without neo-adjuvant chemo and radiotherapy. A retrospective evaluation of 36 patients submitted to lower anterior resection for adenocarcinoma of the rectum was conducted, subdivided into three groups: Group I (n=11), submitted exclusively to surgical treatment; Group II (n=8), submitted to surgical treatment followed by adjuvant chemotherapy; Group III (n=17), submitted to surgical treatment with chemo and neo-adjuvant radiotherapy. The time period was 36 months. Six patients (16.6%) presented recurrence: 1 patient from Group I, 3 patients from Group II and 2 patients from Group III. Overall survival was 88.9%, distributed in the following way: Group I, 80.0%; Group II, 100.0% and Group III, 87.5%. No significant differences in the rates of recurrence and survival were observed between the groups. It is therefore concluded that within the sample the therapeutic methods had similar response, not having been possible to demonstrate the interference of chemo and radiotherapy in the rates of survival or recurrence

A cirurgia ainda é o principal método de tratamento do câncer do reto. Recentemente a quimio e radioterapia neo-adjuvantes têm sido preconizadas, com freqüência cada vez maior, com o intuito de reduzir os índices de recidiva e mortalidade. O objetivo desse estudo foi avaliar, retrospectivamente a sobrevida e a recidiva tumoral de pacientes submetidos a quimioterapia adjuvante, com e sem quimio e radioterapia neoadjuvantes. Foram avaliados retrospectivamente 36 pacientes submetidos a ressecção anterior baixa por adenocarcinoma do reto. Subdivididos em três grupos: grupo I (N=11), submetidos exclusivamente a tratamento cirúrgico; grupo II (N=8), submetidos a tratamento cirúrgico, seguido de quimioterapia adjuvante; grupo III (N=17), submetidos a tratamento cirúrgico com quimio e radioterapia neo-adjuvantes. O período de seguimento foi de 36 meses. Seis pacientes (16,6%) apresentaram recidiva, sendo 1 paciente do grupo I, 3 pacientes do grupo II e 2 pacientes do grupo III. A sobrevida global foi de 88,9%, assim distribuída: grupo I, 80,0%; grupo II, 100,0% e grupo III, 87,5%. Não houve diferença significante nos índices de recidiva nem na sobrevida entre os grupos. Concluiu-se que na amostra estudada os métodos terapêuticos tiveram resposta equivalente, não tendo sido possível demonstrar a interferência da quimio e ou radioterapia nos índices de sobrevida ou recidiva / Surgery continues to be the principal method for treating cancer of the rectum. Recently, chemo and neo-adjuvant radiotherapy have been considered, with increasing frequency, with the intention of reducing the rates of recurrence and mortality. The objective of this study was to evaluate, retrospectively, survival and tumor recurrence in patients submitted to adjuvant chemotherapy, with and without neo-adjuvant chemo and radiotherapy. A retrospective evaluation of 36 patients submitted to lower anterior resection for adenocarcinoma of the rectum was conducted, subdivided into three groups: Group I (n=11), submitted exclusively to surgical treatment; Group II (n=8), submitted to surgical treatment followed by adjuvant chemotherapy; Group III (n=17), submitted to surgical treatment with chemo and neo-adjuvant radiotherapy. The time period was 36 months. Six patients (16.6%) presented recurrence: 1 patient from Group I, 3 patients from Group II and 2 patients from Group III. Overall survival was 88.9%, distributed in the following way: Group I, 80.0%; Group II, 100.0% and Group III, 87.5%. No significant differences in the rates of recurrence and survival were observed between the groups. It is therefore concluded that within the sample the therapeutic methods had similar response, not having been possible to demonstrate the interference of chemo and radiotherapy in the rates of survival or recurrence